DVT Prophylaxis in Hospitalized Patients
For acutely ill hospitalized medical patients at increased risk of thrombosis, use pharmacologic prophylaxis with LMWH, low-dose unfractionated heparin (bid or tid), or fondaparinux—not graduated compression stockings alone. 1
Risk Stratification is Essential
The most critical first step is determining whether your patient is at increased risk for VTE. Do not provide universal prophylaxis to all hospitalized patients—this approach increases bleeding risk without proportional benefit in low-risk patients 2.
High-Risk Medical Patients (Require Prophylaxis):
- Acute heart failure exacerbation
- Acute respiratory insufficiency
- Active infection/inflammatory disease with immobilization
- Acute stroke with leg paralysis
- Active malignancy
- History of prior VTE
Low-Risk Medical Patients (No Prophylaxis Needed):
For patients at low risk of thrombosis, do not use pharmacologic or mechanical prophylaxis 1. The risks outweigh benefits in this population.
Pharmacologic Prophylaxis: First-Line Approach
Choose one of the following equivalent options 1:
- LMWH (e.g., enoxaparin 40 mg SC daily)
- Unfractionated heparin 5,000 units SC bid or tid
- Fondaparinux 2.5 mg SC daily
All three options demonstrate comparable efficacy in preventing VTE, DVT, PE, and mortality 3. Selection should be based on:
- Cost considerations: UFH costs ~$10/day vs LMWH ~$35/day vs fondaparinux ~$60/day 2
- Dosing convenience: Daily dosing (LMWH, fondaparinux) may improve compliance over bid/tid UFH
- Renal function: Low-dose fondaparinux (1.5 mg daily) or LMWH appear safe in renal insufficiency, though robust data are limited 4
LMWH shows a trend toward superiority over UFH and carries lower risk of heparin-induced thrombocytopenia (1/1900 vs 7/1900 with UFH, though not statistically significant) 2, 5.
Duration of Prophylaxis
Continue prophylaxis only during the period of immobilization or acute hospital stay 1. Do not routinely extend prophylaxis beyond discharge. Extended-duration prophylaxis remains investigational and increases bleeding risk without clear benefit in most medical patients 5, 4.
When Anticoagulation is Contraindicated
Active Bleeding or High Bleeding Risk:
Do not use pharmacologic prophylaxis in patients who are actively bleeding or at high risk for major bleeding 1.
Instead, use mechanical prophylaxis:
- Intermittent pneumatic compression (IPC) is preferred over graduated compression stockings 1
- Graduated compression stockings (GCS) alone are NOT recommended for VTE prophylaxis in medical patients 2
Critical caveat: The ACP strongly recommends against GCS due to lack of efficacy and risk of lower-extremity skin damage in medical patients 2. However, ACCP suggests GCS or IPC may be reasonable when anticoagulation is contraindicated 1. This represents a key divergence in guidelines—prioritize IPC over GCS when mechanical prophylaxis is needed.
When bleeding risk decreases, transition from mechanical to pharmacologic prophylaxis 1.
Special Populations
Critically Ill Patients (ICU):
- Use LMWH or LDUH prophylaxis 1
- If bleeding or high bleeding risk: mechanical prophylaxis with IPC until bleeding risk decreases 1
- Do not perform routine ultrasound screening for DVT 1
Cancer Patients (Outpatient):
- Do not use routine prophylaxis unless additional risk factors present (prior VTE, immobilization, hormonal therapy, angiogenesis inhibitors, thalidomide) 1
- If additional risk factors and low bleeding risk: consider prophylactic-dose LMWH or LDUH 1
Common Pitfalls to Avoid
Universal prophylaxis mandates: Performance measures promoting VTE prophylaxis in all patients regardless of risk are inappropriate and may cause net harm in low-risk patients 2
Relying on GCS alone: This is ineffective in medical patients and causes skin complications 2
Extending prophylaxis indefinitely: Bleeding risk increases without clear VTE reduction benefit beyond hospitalization 1, 4
Ignoring bleeding risk: Major bleeding occurs in <1% but must be weighed against VTE risk 5